NCT02559921View on ClinicalTrials.gov

Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

December 31, 2015

Conditions
Rabies
Interventions
BIOLOGICAL

rhRIG（20 IU/kg）

BIOLOGICAL

rhRIG（40 IU/kg）

BIOLOGICAL

HRIG（20 IU/kg）

BIOLOGICAL

rhRIG（20 IU/kg） and vaccine

BIOLOGICAL

rhRIG（40 IU/kg） and vaccine

BIOLOGICAL

HRIG（20 IU/kg） and vaccine

BIOLOGICAL

placebo and vaccine

All Listed Sponsors
lead

Beijing Chaoyang District Centre for Disease Control and Prevention

OTHER

NCT02559921 - Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects. | Biotech Hunter | Biotech Hunter